Joanna S. Yi, MD
Department or Service
- Texas Medical Center
- Developmental therapeutics
Assistant Professor, Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine
|Dana-Farber/Boston Children’s Cancer and Blood Disorders Center||fellowship||Pediatric Hematology/Oncology||2013|
|University of Minnesota||residency||Pediatrics||2010|
|University of Wisconsin School of Medicine and Public Health||medical school||Doctor of Medicine||2007|
Dr. Joanna Yi is a member of the Developmental Therapeutics Program and Leukemia Team and sees patients with acute leukemias and/or on early phase clinical trials. Her clinical interests include solid tumors, leukemia and new drug development.
American Board of Pediatrics
American Board of Pediatrics - Pediatric Hematology/Oncology
|American Association of Cancer Research (AACR)||Member|
|American Society of Clinical Oncology (ASCO)||Member|
|American Society of Hematology (ASH)||Member|
|American Society of Pediatric Hematology and Oncology (ASPHO)||Member|
|Children's Oncology Group (COG)||Member|
|Christian Medical and Dental Association (CMDA)||Member|
Dr. Joanna Yi's translational research focuses on the pre-clinical identification and development of new, targeted small molecules for the treatment of childhood cancers with the purpose of evaluating them in clinical trials. She is especially interested in epigenetic drugs and combining them with other active agents.
Dr. Yi wants to discover new, less toxic, targeted drugs by combining the translational drug discovery techniques of the Center for Drug Discovery at Baylor College of Medicine, with the clinical developmental therapeutics program of Texas Children’s Cancer and Hematology Centers. In the laboratory, Dr. Yi is working with investigators within the Cancer Center to identify and characterize small molecules with clinical promise in challenging pediatric cancers. This includes screening several targets in Ewing sarcoma against the CDD's >3 billion compound library. Additionally, as many cancers seen in children do not have mutations detected by DNA sequencing, Dr. Yi has applied an alternate drug discovery approach to pediatric acute myeloid leukemia (AML), which is looking at the control the expression of genes driving the leukemia. She has already found a druggable target, which hopefully is one of many new targets she can screen for new drugs to eventually bring to children with AML. She also is developing tests of “on-target” effect of these compounds to be used in clinical trials.
Pre-clinical targeted drug development
Clinical application of new targeted drugs and combinations
Developing pharmacodynamics biomarker assays